ZURICH — A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker’s board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks. David Samra, managing director at top 20 investor Artisan Partners and founding partner of International Value Group, said the board needed to strengthen its oversight of acquisitions, calling for action from board chairman Giovanni Caforio. “I think he needs to make changes at the board level. One of them should be on improving the team that’s doing these deals because clearly they have been uninspiring at best,” Samra told Reuters in an interview. “I think that the board needs to improve their oversight of acquisitions... they need to bring in better talent on the board to do that and have an acquisition committee.” Samra, however, said he did not blame CEO Vas Narasimhan, who has overseen a 60 per cent share price rally since he took over in 2018 despite a tough global environment with U.S. tariffs under President Donald Trump, and conflict from Ukraine to Iran. Record share price slide On Tuesday, a muscle-wasting disorder drug acquired through Novartis’ US$12 billion takeover of U.S. firm Avidity failed a late-stage study, sending the company’s shares tumbling more than 10 per cent and wiping nearly US$30 billion off its market value. Novartis’ stock, which had been up some 20 per cent year-to-date before this week’s slide, had already fallen a day earlier after results from heart drug Pelacarsen disappointed investors. Artisan is the first investor to publicly call for board changes, though others have voiced concerns about Novartis’ M&A strategy to Reuters. Public pressure from activist shareholders can often encourage other investors to push for change. “If you do a US$12 billion deal and it goes to zero, the management needs to be penalized for that,” Samra said, while noting that other promising drugs could still emerge from the Avidity acquisition. Novartis said in a statement that its financial guidance was unchanged by recent setbacks and that it had a “broad” pipeline of medicines. “We continue a disciplined and shareholder friendly approach to capital allocation by investing in the organic business, pursuing value-creating bolt-ons, and returning capital to shareholders through a growing annual dividend and share buybacks,” it said. ‘The acquisition track record is not very good’ Samra also cited Novartis’ 2024 acquisition of German biotech MorphoSys as a disappointing deal. Investor enthusiasm faded after Novartis wrote down the value of the acquisition only months later. Many analysts have viewed the latest setbacks as a test of CEO Narasimhan. But Samra said Narasimhan had done a “very good job” running the business, and instead questioned whether the board had exercised sufficient scrutiny over deals. “The acquisition track record is not very good,” Samra said, arguing that deals had destroyed value. “The party is over.” Samra also urged the board to overhaul Novartis’ compensation structure, saying it relies too heavily on adjusted performance measures that exclude writedowns rather than reflecting “real economic outcomes.” --- Reporting by Oliver Hirt in Zurich and Marleen Kaesebier; Editing by Dave Graham, Adam Jourdan and Mark Potter
